CLCD Insider Trading Activity and SEC Form 4 Filings
CLCD insider trading summary
No open-market insider purchases or sales of CoLucid Pharmaceuticals, Inc. (CLCD) have been reported on SEC Form 4 in the past 12 months.
Latest CLCD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 5, 2017 | Linda C. Hogan | Head, Bus. Dev. and Strategy | Sell | $16K (477 @ $33.55) |
| Jan 5, 2017 | Thomas P. Mathers | Chief Executive Officer | Sell | $27K (802 @ $34.25) |
| Jan 5, 2017 | Linda C. Hogan | Head, Bus. Dev. and Strategy | Sell | $21K (600 @ $35.61) |
| Jan 5, 2017 | Linda C. Hogan | Head, Bus. Dev. and Strategy | Sell | $21K (600 @ $34.40) |
| Jan 5, 2017 | Thomas P. Mathers | Chief Executive Officer | Sell | $18K (500 @ $35.60) |
| Jan 5, 2017 | Thomas P. Mathers | Chief Executive Officer | Sell | $7K (200 @ $34.86) |
| Jan 4, 2017 | Linda C. Hogan | Head, Bus. Dev. and Strategy | Sell | $7K (185 @ $36.40) |
| Jan 3, 2017 | Bernice Kuca | Head,Clin. and Reg. Operations | Sell | $28K (772 @ $36.25) |
| Jan 3, 2017 | Matthew D Dallas | Chief Financial Officer | Sell | $53K (1,473 @ $36.25) |
| Jan 3, 2017 | Linda C. Hogan | Head, Bus. Dev. and Strategy | Sell | $26K (718 @ $36.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.